Coen Wiegman is a Lecturer in Respiratory Science within the Airway Disease section of the National Heart & Lung Institute.
Dr. Wiegman obtained Master degrees in Animal Physiology and in Behavioural & Cognitive Sciences at the Faculty Mathematics and Natural Sciences at the University of Groningen, the Netherlands and subsequent a PhD at Paediatrics at the Faculty of Medical Science, at the University of Groningen, the Netherlands.
After his PhD he held a post-doctoral position at the Imperial College London and a Senior Scientist position at the Cambridge University associated pharmaceutical company Paradigm Therapeutics now part of the pharmaceutical company Takeda.
He started his current position in 2009 initially working with Kazuhiro Ito on the role of HDAC2 in in vivo models of COPD.
Dr. Wiegman successfuly completed a RC UK Academic Fellowship in COPD investigating inflammatory mechanisms of histone deacetylases and other co-repressors in suppressing inflammatory gene activation and how these may be harnessed to overcome corticosteroid resistance in COPD.
His current research focuses on the role of inflammation and oxidative stress in the pathophysiology of asthma and COPD using in vitro and in vivo models. In particular, research focuses on the intracellular molecular mechanisms that are involved in the oxidative stress induced alteration of the anti-oxidative stress response, HIF-1α signalling and mitochondrial dysfunction.
et al., 2015, Oxidative stress-induced mitochondrial dysfunction drives inflammation and airway smooth muscle remodeling in patients with chronic obstructive pulmonary disease, Journal of Allergy and Clinical Immunology, Vol:136, ISSN:1097-6825, Pages:769-780